The Galleri Test: What We Know, What We Don't, and Who Should Consider It

What Is the Galleri Test?

Galleri, developed by GRAIL, is a multi-cancer early detection (MCED) blood test that analyzes cell-free DNA (cfDNA) methylation patterns in the bloodstream to detect cancer signals and predict the tissue of origin. It is designed to screen for more than 50 cancer types — the majority of which currently have no standard-of-care screening test — from a single blood draw.

As cells die through normal turnover, they shed small fragments of DNA into circulation. Cancer cells have distinct epigenetic signatures including abnormal methylation patterns, leaving a detectable molecular fingerprint in circulating cfDNA. Machine learning algorithms analyze these patterns, generating a binary result (cancer signal detected / not detected) and, when positive, a predicted tissue of origin. The test costs approximately $949 out of pocket and is available by prescription only.

The PATHFINDER Study

The foundational prospective clinical study supporting Galleri is the PATHFINDER study, published in The Lancet in 2023. PATHFINDER enrolled 6,621 adults aged 50 and older without known active cancer:

• —1.4% of participants had a cancer signal detected (92 individuals)
• —Of those with a positive signal, 38 were ultimately diagnosed with cancer (approximately 41% confirmation rate)
• —Positive predictive value (PPV) — approximately 43% in participants over 50 with additional risk factors
• —Tissue of origin prediction was accurate in approximately 88% of confirmed cancer cases — clinically meaningful for directing subsequent workup
• —Downstream workup burden — median time to diagnostic resolution approximately 79 days; most positive results required CT, PET-CT, or MRI, and some required invasive procedures

Sensitivity: The Number That Requires the Most Attention

Across all cancer types and stages, Galleri's sensitivity in the CCGA and STRIVE data was approximately 51%. This means it misses roughly half of all cancers at the time of the blood draw. Sensitivity improves for cancers with high shedding (ovarian, pancreatic, liver) and for later-stage disease — but for Stage I cancers, sensitivity is substantially lower.

Galleri is not a rule-out test. A negative result meaningfully reduces — but does not eliminate — the probability of occult cancer. A negative result is not a clean bill of health.

Specificity is very high — approximately 99.5%. When the test says cancer signal detected, it is more likely than not that something real is happening, though downstream workup still needs to confirm it.

What Galleri Does Not Replace

• —Colonoscopy — remains the gold standard for colorectal cancer screening
• —Mammography / tomosynthesis — breast cancer screening with established mortality reduction data
• —Low-dose CT (LDCT) — standard for lung cancer screening in qualifying current and former smokers
• —PSA / prostate MRI — prostate cancer surveillance
• —Pap smear / HPV co-testing — cervical cancer screening with decades of outcome data

Galleri's particular value lies in providing a signal for the approximately 70% of cancer deaths that occur in cancer types for which no standard-of-care screening currently exists — pancreatic, ovarian, esophageal, and others.

Who Should Consider the Galleri Test?

Strongest candidacy:

• —Adults 50 and older with a personal or family history of cancers for which no standard screening exists (pancreatic, ovarian, esophageal, gastric, biliary)
• —Individuals with multiple first-degree relatives with cancer diagnoses, particularly at early ages, without an identified hereditary syndrome
• —Patients with BRCA1/2, Lynch syndrome, or other germline mutations where multi-organ surveillance is clinically warranted
• —Patients who have completed all guideline-recommended cancer screening and are seeking supplemental, non-organ-specific early detection

Poor candidates:

• —Adults who have not yet completed standard-of-care cancer screening — Galleri is an add-on, not a starting point
• —Anyone who would not pursue workup following a positive result, due to health status, personal values, or psychological burden
• —Adults under 50 without high-risk features — sensitivity is lower, pre-test probability is lower, yield-to-workup-burden ratio is unfavorable

Bottom Line

The Galleri test represents a genuine scientific advance in cancer detection. The cfDNA methylation platform is biologically sound, the specificity is excellent, and the tissue-of-origin prediction is clinically useful. Its current limitations — moderate overall sensitivity (~51%), absence of mortality endpoint data, and significant downstream workup burden — are real and should be communicated clearly to any patient considering it.

Used appropriately, in patients with genuine risk factors and a clear understanding of what the test can and cannot tell them, Galleri is a reasonable component of a precision cancer surveillance strategy. Used as a substitute for proven screening, it creates false reassurance on the negative end and unnecessary anxiety on the positive end. The distinction comes down to clinical context.

References

1. 1. Schrag D, et al. Blood-based tests for multicancer early detection (PATHFINDER). Lancet. 2023;402(10409):1251–1260.
2. 2. Wolpin BM, et al. STRIVE: a prospective multi-center study of a multi-cancer early detection blood test. J Clin Oncol. 2023;41(suppl 16):LBA5.
3. 3. Liu MC, et al. Sensitive and specific multi-cancer detection using methylation signatures in cell-free DNA (CCGA study). Ann Oncol. 2020;31(6):745–759.
4. 4. Chung DC, et al. Prospective evaluation of a cell-free DNA blood-based test for colorectal cancer screening (ECLIPSE). N Engl J Med. 2024;390(11):973–983.
5. 5. Neal RD, et al. Cell-free DNA-based multi-cancer early detection test in an asymptomatic screening population (NHS-Galleri). PLoS ONE. 2022;17(7):e0265733.